CAR-T targeting BCMA and FcRL5 for relapsed/refractory myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new type of immunotherapy called CAR-T cells that target two proteins (BCMA and FcRL5) on myeloma cells. It is for people whose myeloma has returned or not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have multiple myeloma that has come back after treatment or has not responded well to treatment.
- Your liver and kidney function are within a safe range for this therapy.
- You are not pregnant, breastfeeding, and do not plan to become pregnant for 6 months.
- You do not have a serious active infection, such as HIV or active hepatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell therapy that targets FcRL5 on myeloma cells. It's for people whose myeloma has come back or stopped responding to other treatments, including stem cell transplant.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BCMA on multiple myeloma cells. It is for people whose myeloma has come back or has not responded to other treatments.
This trial tests a new CAR-T cell therapy that targets two proteins (BCMA and CD19) on myeloma cells. It may help patients whose myeloma has come back or stopped responding to previous treatments.
This early trial tests a new CAR-T cell treatment targeting three proteins (CD19, CD22, and BCMA) on myeloma cells. It's for people whose myeloma came back or didn't respond to at least three prior treatments.
This trial tests a new type of treatment using your own immune cells (called CAR-T cells) that target two proteins on myeloma cells: BCMA and GPRC5D. It's for people whose myeloma has come back or stopped responding to standard treatments, and who may have few other options left.
This Phase 1/2 study tests a BCMA-targeting CAR-T cell therapy for people with relapsed or refractory multiple myeloma or related plasma cell diseases. It may help by using your own immune cells, engineered to recognize a specific target on cancer cells.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.